[Hypotensive effect and tolerability of a short course of treatment with prazosin (pratsiol) and hydralazine (apressin) in a cooperative study of new drugs for the prevention of arterial hypertension].
The hypotensive effect and tolerance of a 2-3 week course treatment with pratsiol (n = 59) and apressin (n = 60) were studied in patients with stage II essential hypertension and symptomatic arterial hypertension requiring no special therapy (diastolic arterial pressure in the horisontal position being 95 mm Hg and over). Seven patients were treated with apressin and pratsiol for 14 days under blind cross-over conditions. When used along for 2-3 weeks, apressin and pratsiol induced a hypotensive effect in 53% and 75% of the patients (p less than 0.05), respectively. When used in conjunction with hydrochlorothiazide, the hypotensive effect of apressin was 85%, that of pratsiol 93%. The daily effective dose of apressin equalled 155 +/- 9.9 mg, of pratsiol 9.3 +/- 0.6 mg. Side-effects of apressin were observed 3 times as often as with pratsiol (79% and 27%, respectively; p less than 0.01). The rate of discontinuation of apressin for side-effects reached 35% of the patients, whereas in pratsiol treatment it was only 1.6%.
D000328:Adult; D004359:Drug Therapy, Combination; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D013997:Time Factors
D011799:Quinazolines; D006852:Hydrochlorothiazide; D006830:Hydralazine; D011224:Prazosin
Gipotenzivnyĭ éffekt i perenosimost' korotkogo kursovogo lecheniia prazosinom (pratsiolom) i gidralazinom (apressinom) v kooperativnom issledovanii po izucheniiu novykh preparatov v profilaktike arterial'noĭ gipertenzii (KIPPAG).